Mirogabalin - Daiichi Sankyo Company

Drug Profile

Mirogabalin - Daiichi Sankyo Company

Alternative Names: DS 5565

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Acetic acids; Aminobutyric acids; Analgesics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Neuropathic pain; Postherpetic neuralgia
  • Phase III Pain

Most Recent Events

  • 12 Sep 2018 Efficacy and adverse events data from two phase III trials in Neuropathic pain and Postherpetic neuralgia presented at the 17th World Congress on Pain (WCP-2018)
  • 24 Jun 2018 Biomarkers information updated
  • 27 Apr 2018 Discontinued - Phase-III for Pain in USA, Austria, Hungary, United Kingdom, Slovakia, Estonia, Lithuania, Latvia, Bulgaria, Poland, Bulgaria, Romania, Portugal, Spain, Slovenia, Czech Republic, Denmark, Finland, France, Germany, Netherlands, Norway and Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top